693P Impact of one-week hydration after each three-weekly concurrent cisplatin on the tolerance among locally advanced head and neck cancer patients receiving chemoradiotherapy

Abstract

Three-weekly high-dose cisplatin (100 mg/m2) is considered the standard systemic regimen given concurrently with postoperative or definitive radiotherapy in locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). Concurrent chemoradiation (CRT) with high-dose cisplatin is associated with 30% of acute kidney injury (AKI). The aims of this study were to investigate the impact of our outpatient protocol of 7 day hydration after each cisplatin administration on the tolerance.